Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash from Financing Activities (2016 - 2026)

Lexaria Bioscience's Cash from Financing Activities history spans 12 years, with the latest figure at $3.0 million for Q1 2026.

  • Quarterly results put Cash from Financing Activities at $3.0 million for Q1 2026, up 25873.16% from a year ago — trailing twelve months through Feb 2026 was $8.2 million (down 12.69% YoY), and the annual figure for FY2025 was $6.0 million, down 41.39%.
  • Cash from Financing Activities for Q1 2026 was $3.0 million at Lexaria Bioscience, down from $3.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $5.0 million in Q2 2024 to a low of -$121687.0 in Q3 2023.
  • The 5-year median for Cash from Financing Activities is $1.7 million (2023), against an average of $1.9 million.
  • The sharpest move saw Cash from Financing Activities plummeted 986.01% in 2023, then surged 25873.16% in 2026.
  • Year by year, Cash from Financing Activities stood at -$11205.0 in 2022, then skyrocketed by 16337.13% to $1.8 million in 2023, then surged by 138.84% to $4.3 million in 2024, then fell by 20.05% to $3.5 million in 2025, then decreased by 12.38% to $3.0 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $3.0 million, $3.5 million, and $1.7 million for Q1 2026, Q4 2025, and Q2 2025 respectively.